Close

Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

Go back to Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

Karuna Therapeutics Inc. (KRTX) PT Raised to $167 at JMP Securities, 'Additional Evidence Continues to Support KarXT's Advantages'

February 25, 2021 4:15 PM EST

JMP Securities analyst Jason Butler raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $167.00 (from $122.00) while maintaining a Market Outperform rating.

The analyst comments "Karuna announced 4Q20 earnings and provided business updates highlighted by interim Phase 1b healthy elderly volunteer... More